LightNews LightNews
banner
bioaccess.bsky.social
@bioaccess.bsky.social
13 followers 110 following 4 posts
Posts Replies Media Videos
Reposted
thecancersurvivorsclub.com
Behind the FDA approval of Dordaviprone (Modeyso) lies new hope for patients with #glioma. The first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma marks a milestone for children & young adults facing this rare, aggressive brain tumour.

www.targetedonc.com/view/behind-...
Behind the FDA Approval of Dordaviprone, a New Hope for Glioma
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
www.targetedonc.com
August 25, 2025 at 7:29 AM
Reposted
pbsnews.org
Between the end of February and mid-August, funding ceased for 383 studies that were testing treatments for conditions including cancer, heart disease and brain disease. https://to.pbs.org/47KbPDE
NIH cuts affected over 74,000 patients enrolled in experiments, report finds
Between the end of February and mid-August, funding lapsed for 383 studies that were testing treatments for conditions like cancer, heart disease and brain disease.
www.pbs.org
November 17, 2025 at 10:31 PM
bioaccess.bsky.social
A beautiful tribute from CJ Carr: 100 Years of Love in 5 Years of Life
open.substack.com/pub/biotecha...
November 22, 2025 at 1:13 AM
bioaccess.bsky.social
The Outliers Who Reshape Treatments and Patient Access
open.substack.com/pub/biotecha...
November 20, 2025 at 9:13 PM
bioaccess.bsky.social
When One Patient Changes Everything
open.substack.com/pub/biotecha...
When One Patient Changes Everything
FDA's new plausible mechanism pathway
open.substack.com
November 19, 2025 at 11:13 AM
bioaccess.bsky.social
When the Ground Shifts: FDA Volatility and the Real Cost to Patients
open.substack.com/pub/biotecha...
November 19, 2025 at 1:44 AM